BeneFIX: For once-weekly prophylaxis and on-demand use​​​​​​​2

Resources for Patients and Caregivers

Pfizer Hemophilia is more than just factor—
It's support for your eligible patients

Pfizer Patient Affairs Liaisons

Pfizer Patient Affairs Liaisons are professionals dedicated to serving the rare disease community by connecting patients, caregivers, and patient advocacy organizations with Pfizer Rare Disease tools and resources. A Pfizer Patient Affairs Liaison’s work is guided by the principles of compassion, commitment, and connection.

Pfizer Patient Affairs Liaisons are not measured or awarded based on sales performance nor will they ask patients to switch products.
​​​​​​​
Your patients can find their local Pfizer Patient Affairs Liaison on pfizerpal.com.

Visit pfizerpal.com

BeneFIX Patient Brochure

Educates patients on important information about BeneFIX and available support tools.

Download now

Financial Support Options

Pfizer Hemophilia Connect

If you’re looking for a one-stop source for all Pfizer Hemophilia resources and support programs, turn to Pfizer Hemophilia Connect.

Learn more about Pfizer Hemophilia Connect

Terms and conditions apply.

Factor Savings Card

If your patients need help paying for their therapy, they may be eligible for the Pfizer Factor Savings Card.

​​​​​​​Terms and conditions apply.

Learn more about the Factor Savings Card


Trial Prescription Program

If your patients have been prescribed BeneFIX for the first time, they may be eligible to participate in the Pfizer Factor Product Trial Prescription Program.

​​​​​​​Terms and conditions apply.

Learn more about the Trial Prescription Program



References:​​​​​​​
  1. Center for Biologics Evaluation and Research, US Food and Drug Administration, US Department of Health and Human Services. CBER Approval Letter, Coagulation Factor IX (Recombinant), Genetics Institute, Inc. February 11, 1997. Accessed May 12, 2021. wayback.archive-it.org/7993/20170723024338/https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm057039.htm
  2. BeneF​​​​​​​IX. Prescribing information. Pfizer Inc.; 2021.

Support & Resources

  • Resources for Patients and Caregivers
  • Additional Resources
View Support & Services

Dosing options to meet patients' needs

Learn how you can personalize your patients’ dosing.

See available vial sizes

** This is an optional area where footnotes can live.

  • BeneFIX is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein (CHO).
  • Hypersensitivity reactions, including anaphylaxis, have been reported with BeneFIX. Closely monitor patients for signs and symptoms of acute anaphylaxis, particularly during the early phases of initial exposure to the product. Immediately discontinue the administration of the product and initiate appropriate treatment if symptoms occur.
  • Patients may develop hypersensitivity to hamster protein as BeneFIX contains trace amounts.
  • BeneFIX has been associated with the development of thromboembolic complications, including in patients receiving continuous infusion through a central venous catheter. The safety and efficacy of BeneFIX administration by continuous infusion have not been established.
  • Neutralizing antibodies (inhibitors) have been reported following the administration of BeneFIX. If expected plasma factor IX activity levels are not attained, or if the patient presents with an allergic reaction, or if bleeding is not controlled following an expected dose of BeneFIX, perform an assay that measures factor IX inhibitor concentration.
  • The most common adverse reactions (>5%) from clinical trials were fever, cough, nausea, injection site reaction, injection site pain, headache, dizziness, and rash.

BeneFIX, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. 

Limitation of use:

BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Please see full Prescribing Information for BeneFIX.

Indication

BeneFIX, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. 

Limitation of use:
BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Please see full Prescribing Information for BeneFIX.